Company profile: Amal Therapeutics
1.1 - Company Overview
Company description
- Provider of proprietary oncology immunisation technology and therapeutic cancer vaccines, built on its KISIMA platform that delivers multiple antigens in a single vaccine. Offerings include ATP128, a clinical-stage therapeutic vaccine targeting metastatic colorectal cancer, and collaboration opportunities in immuno-oncology.
Products and services
- ATP128: Clinical-stage therapeutic vaccine engineered to target metastatic colorectal cancer and stimulate immune responses against cancer cells
- KISIMA®: Proprietary immunisation technology platform that architects therapeutic vaccine assemblies and delivers multiple antigens in a single vaccine, enabling multi-antigen payload integration for oncology applications
- Therapeutic cancer vaccines: Oncology-focused vaccine products developed to strengthen immune recognition and killing of tumor cells in cancer patients, enhancing targeted anti-tumor immune responses
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Amal Therapeutics
Crossbow Therapeutics
HQ: United States
Website
- Description: Provider of next-generation immunotherapies, including T-Bolt therapies that precisely target cancer cell antigens, and CBX-250, a T-cell engager for myeloid leukemia demonstrating potency and specificity in preclinical models.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crossbow Therapeutics company profile →
Myriad Genetics
HQ: United States
Website
- Description: Provider of genetic testing and molecular profiling solutions, including hereditary cancer risk assessment (MyRisk), pharmacogenomic testing for mental health medications (GeneSight), prostate cancer aggressiveness evaluation (Prolaris), tumor genomic profiling (Precise), carrier screening (Foresight), and non-invasive prenatal screening (Prequel).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Myriad Genetics company profile →
GigaGen
HQ: United States
Website
- Description: Provider of recombinant biotherapeutic discovery and development, advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world's first recombinant polyclonal hyperimmune gammaglobulin.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GigaGen company profile →
PanTher Therapeutics
HQ: United States
Website
- Description: Provider of localized cancer therapies leveraging the Sagittari platform to optimize drug dose and duration for high-dose, tumor-targeted treatment with minimal systemic exposure. Offers PTM-101, a clinical-stage candidate delivering high concentrations of paclitaxel to pancreatic tumors via minimally invasive laparoscopy, and exploratory programs for pancreatic, colon, and lung cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PanTher Therapeutics company profile →
Prelude Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule cancer therapies and precision antibody-drug conjugates, including PRT3789, a selective SMARCA2 degrader for SMARCA4-deficient tumors; PRT2527, a highly selective CDK9 inhibitor in Phase 1; PRT3645, a next-generation CDK4/6 inhibitor in preclinical studies; and ADCs developed with AbCellera.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prelude Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Amal Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Amal Therapeutics
2.2 - Growth funds investing in similar companies to Amal Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Amal Therapeutics
4.2 - Public trading comparable groups for Amal Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →